Author: Neutrolis, Inc.

Posted Date:

April 15, 2026

Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer

Neutrolis, Inc.

April 15, 2026
Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein

Neutrolis, Inc.

April 2, 2026
Neutrolis Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors as Executive Director

Neutrolis, Inc.

February 23, 2026